Name: Defensive Symptoms and When to Blunt Them
Creator: Realised
Published: 2026-08-01

Summary

Cough, fever, nausea, pain, low mood and their relatives are evolved defences, not malfunctions — but "it evolved" does not mean "this firing, right now, is useful," so some symptom relief is costless comfort, some carries a real trade, and a small set of situations demand medication or urgent care.

Why Moderate

The hub sits at Moderate overall — an honest average across sub-areas whose tiers genuinely diverge, with the label doing routing work rather than claiming one uniform evidence grade.

Why not the tier above (Strong Evidence): the intellectual spine of the entry — the smoke detector principle — is a mathematical argument that has never been empirically tested against outcomes, and several load-bearing sections (sickness behaviour's human outcome data, the sleep-to-recovery bridge, the entire low-mood section) rest on mechanism, observation or theory rather than interventional evidence. An entry whose organising claim is untestable theory cannot honestly wear the top interventional label.

Why not the tier below (Emerging): several sub-areas carry evidence as strong as anything in the KB — the Cochrane cough review (29 RCTs), the ACOG antiemetic guideline (RCT-backed), oral rehydration's mortality record, and the WAO anaphylaxis guidance (universal consensus). Grading the hub Emerging would misrepresent the majority of its practical guidance, which is guideline-grade.

Per-sub-area split: framework — Foundational as reasoning, untested as prediction · cough — Strong Evidence (that the evidence is inadequate) · sickness behaviour — Moderate · sleep-during-illness — Moderate · pregnancy-nausea hypothesis — Emerging · pregnancy-nausea treatment — Strong Evidence · diarrhoea — Strong Evidence (dysentery bar on weaker primary studies) · acute pain signal — Foundational · low mood — Emerging (theory only) · anaphylaxis/emergency category — Foundational · fever and injury inflammation — inherited from the sibling entries, not graded here.

Practical takeaway

This is the hub's routing map. Each row: what the defence is for, how strong the adaptive-function evidence is, what suppression is documented to cost, when treating is sensible, and when to escalate. Depth lives in the owning entries.

Cough (simple respiratory infection)
• Adaptive function: airway clearance — physiological consensus.
• Suppression cost: none documented; equally, effectiveness of OTC cough medicines is not demonstrated (Strong Evidence that the trial base is inadequate either way).
• Treat when: cough is wrecking sleep — honey, humidity and time are the evidence-honest toolkit; buying an OTC product is a low-stakes personal call.
• Escalate when: cough with breathing difficulty, coughing blood, high persistent fever, or lasting beyond three weeks.
• Routes to: common_cold_prevention_and_treatment.

Sickness behaviour (lethargy, appetite loss, withdrawal)
• Adaptive function: energy conservation for the immune response — Moderate; mechanism solid, human outcome data thin.
• Suppression cost: the real "suppression" here is forcing activity, and the products sold to enable it barely address the lethargy anyway. No trial quantifies the cost of pushing through; the mechanism argues against it.
• Treat when: not a treating question — a resting question. Take the rest; symptom relief alongside rest is compatible with it.
• Escalate when: confusion, inability to stay awake, or sickness behaviour wildly out of proportion to the apparent illness.
• Routes to: fever_and_sickness_behaviour_evidence, illness_inflammation_and_sleep_disruption, immune_function_cross_pillar_optimisation.

Night-time symptoms during illness
• Adaptive function: none — night cough and aches are not separately adaptive; sleep is.
• Suppression cost: none documented; sleep loss itself carries a documented immune cost (Moderate — roughly fourfold cold susceptibility below six hours in the challenge study).
• Treat when: symptoms are costing you sleep. This is the hub's clearest case of suppression being pro-recovery, not anti-recovery.
• Escalate when: night symptoms that suggest the red-flag list below.
• Routes to: illness_inflammation_and_sleep_disruption.

Nausea and vomiting (including pregnancy)
• Adaptive function: toxin/pathogen expulsion and aversion — Emerging for the pregnancy embryo-protection version, with reverse causation unresolved.
• Suppression cost: none documented for guideline-endorsed antiemetic use in pregnancy (Strong Evidence for safety of first-line agents).
• Treat when: nausea is degrading eating, hydration or life — in pregnancy, first-line treatment is endorsed care, not a moral failure.
• Escalate when: inability to keep fluids down, weight loss, signs of dehydration — hyperemesis is an urgent-care condition, full stop.
• Routes to: stays with this hub; clinical care sits with the treating clinician.

Diarrhoea
• Adaptive function: pathogen expulsion — plausible, but the therapeutic target is hydration, not stool count.
• Suppression cost: real but narrow — antimotility drugs as sole therapy with bloody stool or high fever risk prolonging invasive infection (guideline consensus on older evidence); avoided in young children.
• Treat when: simple, afebrile, non-bloody traveller's diarrhoea — loperamide is guideline-permitted, alone or alongside antibiotics. Rehydrate regardless: oral rehydration is the intervention with the mortality evidence.
• Escalate when: blood in stool, high fever, severe dehydration, or a young child affected.
• Routes to: stays with this hub.

Acute pain
• Adaptive function: damage signalling — Foundational; its congenital absence produces serial unnoticed injury.
• Suppression cost: context-dependent — the injury-inflammation trade is the sibling's territory, where the evidence for a cost is animal-strong and human-thin and NSAIDs remain first-line for some injuries; the classic feared failure mode is masking pain in order to keep loading damaged tissue.
• Treat when: pain is understood and comfort is the goal — comfort is a legitimate treatment goal.
• Escalate when: pain that is severe, unexplained, or accompanied by red-flag features — for an injury: inability to bear weight, visible deformity, numbness or loss of sensation; generally: chest pain, worst-ever headache, neurological deficit.
• Routes to: acute_injury_inflammation_ice_and_nsaids, muscle_soreness_recovery_doms.

Low mood
• Adaptive function: proposed effort-regulation and disengagement functions — Emerging, theory only.
• Suppression cost: none demonstrated; no trial shows untreated low mood resolves better.
• Treat when: mood is impairing life — treatment of depression is appropriate on the adaptive framework's own logic, and nothing here supports stopping a prescribed medicine.
• Escalate when: thoughts of self-harm, inability to function, symptoms persisting beyond a couple of weeks — clinical care, not philosophy.
• Routes to: anhedonia_reward_recovery, stress_response_is_adaptive_but_context_dependent.

Fever
• One line, then route: fever has genuine antimicrobial function, antipyretics are genuine comfort in self-limiting illness, and the best human trials have not shown that comfort dosing worsens outcomes — the trade in both directions, the paediatric specifics and the danger thresholds are owned by fever_and_sickness_behaviour_evidence.

Allergic responses
• One line, then route: hay fever is a defence misfiring against a harmless target — suppression is the correct default; the sleep-protecting management detail is owned by hay_fever_allergic_rhinitis_sleep_protocol. The catastrophic end of the same machinery, anaphylaxis, sits in the red flags below.

Defences that ARE the emergency
• Anaphylaxis (swelling of lips/tongue/throat, breathing difficulty, collapse after an exposure): intramuscular epinephrine first-line, immediately — delay, not overuse, is the documented killer. Hyperemesis gravidarum. Febrile status epilepticus. Cytokine storm. These are not suppress-or-respect decisions. They are ambulance decisions.

Evidence detail

Why This Entry Exists

Almost everyone who feels ill faces the same quiet decision several times a year: take something to make the symptom stop, or leave it alone. The advice environment around that decision is split into two confident camps, and both are wrong in a way that costs people. One camp treats every symptom as a malfunction to be silenced so you can get back to work. The other treats every symptom as body-wisdom that must never be touched. The honest evidence sits in between, and it sits differently for each defence — which is why this entry exists as a hub: it holds the framework once, walks each defence briefly, and routes to the entries that carry the depth.

The organising idea is the smoke detector principle, formalised by the evolutionary psychiatrist Randolph Nesse. Defences like cough, fever, anxiety, nausea and pain are regulated by the same signal-detection logic engineers use for alarms: when a defence is cheap to express and the harm it protects against is catastrophic, the optimal evolved threshold fires many false alarms — exactly as a smoke detector that never misses a fire must also shriek at burnt toast. This principle cuts both ways, and stating only one direction is the signature of an agenda. It explains why defences exist and deserve a moment's respect before suppression. It equally explains why blocking any single firing is often harmless — because a system tuned to fire early and often produces mostly overshoots. Anyone quoting the smoke detector principle in only one direction is misusing it.

One rail runs through everything below and is not negotiable: comfort is a legitimate treatment goal. Feeling less awful while your body does its work is a reasonable thing to want and often a reasonable thing to buy, and nothing in this entry sneers at it. Equally, nothing in this entry is a reason to stop or avoid a medicine a clinician has prescribed, and a small set of red-flag situations — laid out unmissably below — are not philosophical territory at all: they are emergencies.

What bad advice this protects against, in all directions:
• "Never suppress a symptom — your body knows best." Wrong because the smoke detector principle itself predicts that many individual firings are false alarms; because the best-studied suppressions (night-time symptom relief that restores sleep, antiemetics in pregnancy, loperamide in simple traveller's diarrhoea) show no documented outcome cost; and because in the dangerous-defence category — anaphylaxis above all — "trusting the body" kills.
• "Symptoms are just malfunctions — medicate everything and power through." Wrong because sickness behaviour is an organised energy-conservation strategy, not weakness, and the marketed promise of working through infection at full capacity overrides the one defence with the strongest adaptive logic — rest — while the products doing the overriding often barely work.
• "Cough medicine gets you through the workday." Wrong on the evidence: a Cochrane review of twenty-nine randomised trials could not show over-the-counter cough medicines work at all. The irony is load-bearing — the suppression people buy most is the one with the least evidence of doing anything, which is also why buying it is rarely dangerous.
• "Pregnancy nausea protects your baby, so treat nothing." Wrong twice over: the embryo-protection hypothesis is an interesting, partially supported idea with a live reverse-causation confound, not established fact; and first-line antiemetics are guideline-endorsed as safe, while the severe end of the spectrum — hyperemesis, with dehydration and weight loss — is a treat-urgently condition, not a defence to respect.
• "Loperamide traps the toxins in — let diarrhoea run." Overclaimed: guidelines do bar antimotility drugs as sole therapy when there is bloody stool or high fever, but the same guidelines permit them in simple, afebrile traveller's diarrhoea — and the intervention that actually saves lives, rehydration, is the one neither camp monetises.
• "Low mood is a message, not a disease — come off the pills." Dangerous distortion: the adaptive-mood literature is theory about ordinary low mood, its own authors state that much clinical depression is the system misfiring, and this entry never tells anyone to stop a prescribed medicine.

OWNS: the smoke detector framework stated canonically in both directions; the routing map across defences (cough, sickness behaviour, sleep-during-illness, nausea including pregnancy, diarrhoea, acute pain as a signal, low mood as a signal); the defences-that-are-themselves-dangerous category and its red flags.

DEFERS: fever and antipyretic trade-offs to fever_and_sickness_behaviour_evidence; injury inflammation, ice and NSAIDs to acute_injury_inflammation_ice_and_nsaids; soreness-as-signal to muscle_soreness_recovery_doms; cold prevention and treatment specifics to common_cold_prevention_and_treatment; sleep–immune mechanics to illness_inflammation_and_sleep_disruption; clinical depression and reward recovery to anhedonia_reward_recovery; the general adaptive-stress logic to hormesis_and_adaptive_stress and stress_response_is_adaptive_but_context_dependent; allergy management to hay_fever_allergic_rhinitis_sleep_protocol.

Evidence

Read the tiers, not the thesis. The framework at the top of this entry is a piece of evolutionary reasoning — internally sound, widely accepted, and never empirically tested against outcomes in any trial. Underneath it, the per-symptom evidence ranges from some of the strongest findings in medical history (oral rehydration) to hypotheses that remain genuinely open (pregnancy nausea as embryo protection). Each claim below is labelled by evidence type. Where the evidence is absent, the absence is stated as an absence — not papered over in either direction.

The framework

1. The smoke detector principle — evolutionary reasoning; a signal-detection/mathematical argument, not an empirical trial. Nesse (2001) formalises it: expected-value analysis shows a low-cost, all-or-none defence should trigger far below the threshold at which harm is certain, so most individual firings are false alarms. The popular grounding is Nesse & Williams, Why We Get Sick (1994). The argument is internally sound and standard in evolutionary medicine, but it makes no claim about any specific symptom in any specific person, and it licenses both "respect the defence" and "suppress this instance." Evidence label: Foundational as a framework, with the explicit caveat that it is theory, not trial data. Cui bono: wellness media quotes only the "defences are wise" half to sell never-medicate naturalism; suppress-everything framing quotes only the "false alarm" half. Honestly stated, the principle supports neither camp.

Cough

2. Over-the-counter cough medicines for acute cough have no good evidence of effectiveness. — HUMAN RCT evidence: Cochrane systematic review of 29 randomised trials, 4,835 participants (3,799 adults, 1,036 children), covering antitussives, expectorants, mucolytics, antihistamines and combinations. Smith, Schroeder & Fahey (2014 update) conclude there is no good evidence for or against effectiveness — trials were heterogeneous, often industry-funded, with conflicting results of uncertain clinical relevance. Two absences must be stated precisely: this is absence of evidence of benefit, not proof of harm; and no evidence base shows that suppressing cough in a simple upper respiratory infection prolongs the illness. Evidence label: Strong Evidence — for the conclusion that the evidence is inadequate. Cui bono: a multi-billion cough-and-cold market sells products a Cochrane review cannot show work; the naturalist counter-market spins the same review as "medicine is a scam," skipping that honey, humidity and time are what both camps are actually left with.

Sickness behaviour and rest

3. Sickness behaviour — lethargy, appetite loss, withdrawal — is an organised, evolved energy-conservation strategy, not weakness. — Rodent-and-animal observation plus evolutionary reasoning. Hart (1988) is the founding statement: across sick animals and humans, the withdrawal-lethargy-anorexia cluster at infection onset is a coordinated, cytokine-driven motivational state that conserves energy for the febrile immune response. Later cytokine work (IL-1 and endotoxin models, largely in rodents) confirmed the state is centrally orchestrated. The honest gap: direct human outcome data showing that fighting through sickness behaviour worsens outcomes is thin — the exertion-during-infection and presenteeism evidence is largely observational, and no human trial has randomised "rest versus push through" a live infection. Evidence label: Moderate — mechanism well established, human outcome data limited. The practical read is the hub's most useful inversion: the strongest "respect the defence" move is not refusing medicine — it is actually resting, which no tablet removes from you. Cui bono: "day-and-night cold and flu" products are explicitly marketed to override lethargy so you can keep working — monetised presenteeism; the naturalist side monetises the same science as "take nothing," but the defence being respected here is rest, which no OTC medicine touches either way.

Sleep during illness

4. Short sleep predicts sharply higher susceptibility to catching a cold — the anchor for symptom relief that restores sleep being a legitimately pro-recovery use of suppression. — Human observational sleep exposure embedded in an experimental viral-challenge design; not a sleep RCT. Prather et al. (2015): 164 healthy adults wore actigraphy for a week, were then experimentally inoculated with rhinovirus and quarantined. Those sleeping under six hours a night were markedly more likely to develop a verified clinical cold than those over seven — roughly four times the odds — independent of pre-challenge antibodies, demographics, season, BMI, psychology and health practices. Frame it carefully: the virus was experimental but the sleep was observational, so this shows short sleep predicts susceptibility; the step to "a symptom-relieved night's sleep speeds recovery from an established illness" is a reasoned bridge, not a tested result. Evidence label: Moderate. Cui bono: night-time cold-and-flu marketing leans on exactly this logic — which happens to be directionally sound, a thing this entry can say without endorsing any product; the never-suppress camp has no answer to the sleep-loss cost of an untreated night cough and tends to omit it.

Nausea, including pregnancy

5. Pregnancy nausea as embryo protection is a coherent, partially supported hypothesis — not established fact. — Human observational synthesis plus evolutionary reasoning; no experimental test is possible. Flaxman & Sherman (2000), building on Profet (1992): symptoms peak at weeks 6–18, when organogenesis is most chemically vulnerable; in all nine studies they reviewed, women with nausea and vomiting had lower miscarriage rates than women without; aversions cluster on meats, strong-tasting vegetables, alcohol and caffeinated drinks. The central unresolved confound, acknowledged by the authors and their critics alike, is reverse causation: a hormonally vigorous, viable pregnancy may cause both the nausea and the lower miscarriage risk, so the association does not prove the nausea protects anything. Competing accounts (by-product of placental signalling) remain live. Evidence label: Emerging. Whatever its evolutionary origin, the hypothesis is not a reason to refuse treatment — see the next claim. Cui bono: naturalist pregnancy content uses this hypothesis to shame antiemetic use — an overreach the data do not support and that harms women with severe symptoms. There is no meaningful suppress-side lobby here; the asymmetry itself is worth naming.

6. Treating pregnancy nausea is safe, guideline-endorsed first-line care — and hyperemesis gravidarum is a defence-turned-dangerous state that requires urgent treatment. — HUMAN RCT-backed clinical guideline. ACOG Practice Bulletin No. 189 (2018): pyridoxine (vitamin B6), alone or with doxylamine, is safe and effective first-line pharmacotherapy, backed by placebo-controlled trials, with escalation options beyond it. Hyperemesis gravidarum — severe vomiting causing dehydration, electrolyte derangement and weight loss — is explicitly a treat-urgently condition. One honest wrinkle: reanalysis controversy has surrounded the effect size of some doxylamine-pyridoxine trials, so the safety consensus is firmer than the magnitude-of-benefit estimate. Evidence label: Strong Evidence. Cui bono: branded doxylamine-pyridoxine has been marketed hard off modest effect sizes — the suppress-side conflict; the never-suppress side's "nausea is protective" framing delays care for hyperemesis, which is the graver harm.

Diarrhoea

7. Rehydration matters far more than stopping stools; antimotility drugs are barred as sole therapy in dysentery but safe in most simple traveller's diarrhoea. — HUMAN RCT and systematic review for rehydration and the loperamide-adjunct trials; clinical guideline resting partly on older observational and mechanistic evidence for the dysentery bar. Three edges, all of which must be held at once. (a) Oral rehydration solution is one of the most life-saving interventions in medical history: a pooled fixed-effect meta-analysis of community ORS-promotion studies found a roughly 69% relative reduction in diarrhoeal mortality — a pooled estimate resting on a small number of mortality studies, so precise, but on a thin base — with separate modelled estimates that up to 93% of diarrhoeal deaths are preventable at full coverage; ORS is credited with tens of millions of lives since the 1970s, and WHO/UNICEF make rehydration plus zinc the core of management. Stopping stool output is not the therapeutic target. (b) Guideline consensus (IDSA 2017; ACG 2016; drug labelling) bars antimotility agents as primary therapy where there is bloody diarrhoea or high fever — risk of prolonging invasive infection, with a historical haemolytic-uraemic-syndrome concern in children; loperamide is generally avoided in young children altogether. This bar rests more on older observational and mechanistic evidence than on modern trials. (c) The same guidelines permit loperamide in afebrile, non-bloody traveller's diarrhoea; meta-analytic evidence shows antibiotic plus loperamide gives higher clinical-cure odds than antibiotic alone, and a systematic review found no proof antibiotics beat loperamide in mild-to-moderate cases — so do not overclaim the caution. Evidence label: Strong Evidence overall, with the dysentery bar resting on weaker primary studies than the rehydration and adjunct findings. Cui bono: OTC antidiarrhoeal marketing sells travel and workday continuity and never mentions the bloody-stool exclusion; the naturalist "let it all out, loperamide traps the toxins" framing extends a real, narrow caution to all diarrhoea, which the guidelines contradict. Rehydration — the part that saves lives — is the part neither camp monetises.

Acute pain

8. Acute pain is a protective signal — the textbook demonstration is congenital insensitivity to pain, where its absence leads to repeated unnoticed injury. — Human observational (a natural genetic experiment) plus universal physiological consensus. Cox et al. (2006) mapped congenital inability to experience pain in three consanguineous families to loss-of-function mutations in SCN9A, the gene for the Nav1.7 sodium channel of nociceptive neurons — individuals otherwise neurologically normal who accumulate burns, fractures and orthopaedic damage precisely because the alarm never sounds. The trap in this section is scope creep: chronic pain frequently outlives any protective function (central sensitisation decouples the signal from tissue damage), and that entire territory belongs to its own entries — the hub carries only the acute-signal line. Evidence label: Foundational for the acute-signal claim. Cui bono: analgesic marketing sells masking pain to keep performing — the injury-and-NSAID trade is the sibling entry's territory; the never-suppress camp romanticises pain tolerance. Comfort is a legitimate treatment goal, and this entry says so without apology.

Low mood

9. Low mood after loss may serve functions — a hypothesis about ordinary mood, never a claim that depression is good or should go untreated. — Evolutionary reasoning; a theoretical review with no interventional evidence. Nesse (2000) reviews proposed functions of low mood — signalling need for help, yielding in status conflict, disengaging from unreachable goals, conserving effort in unpropitious situations — and argues mood evolved to regulate effort allocation. Nesse himself is explicit that clinical depression is frequently a dysregulated, pathological state: on his own smoke-detector logic, even if low mood has functions, much depression is the system misfiring, and treatment is appropriate. No trial shows untreated low mood resolves better; that absence is stated as an absence. Evidence label: Emerging, theory only. This hub routes all clinical territory to the depression and reward-recovery entries, and never advises anyone to stop a prescribed medicine. Cui bono: anti-psychiatry and wellness content monetises "depression is a message, not a disease" — a distortion of Nesse; pharma historically monetised the opposite flattening, in which every sadness became a target. Both flattenings are wrong.

Defences that are themselves the danger

10. A small set of defences are catastrophic overshoots that demand immediate suppression or urgent care — anaphylaxis is the anchor. — Clinical guideline and universal consensus; ethics precludes randomised trials of withholding treatment. The World Allergy Organization's 2020 guidance (Cardona et al.): intramuscular epinephrine is unambiguous first-line treatment for anaphylaxis, and the documented real-world failure is under-use and delay, not overuse. This inverts the hub's default frame and must be said plainly: here the evolved defence — a systemic mast-cell response — is itself the lethal event, and "respecting the body" is fatal. The category's other members (hyperemesis gravidarum, covered above under the pregnancy guideline; febrile status epilepticus; cytokine storm) are clinically standard examples; the latter two were not separately searched in this authoring pass and carry no pinned citation here — flagged for authoring-time pinning rather than fabricated. Evidence label: Foundational for the epinephrine claim; the unpinned members are stated as unpinned. Cui bono: neither market wins in this category, which is precisely the point — never-suppress ideology is at its most dangerous exactly here, and the red flags below are written to be unmissable.

Fever and injury inflammation — routing only

11. The two most-studied suppression questions live in the sibling entries, and this hub deliberately carries no figures for them. — Routing note; no claim made at hub level. Fever's antimicrobial function versus antipyretic comfort in self-limiting illness is the territory of fever_and_sickness_behaviour_evidence — including the counterweight, which must carry full weight there: the best human antipyretic trials have not shown that comfort dosing worsens outcomes. The blunting of adaptive inflammation by NSAIDs and ice in some healing contexts is the territory of acute_injury_inflammation_ice_and_nsaids — where the caution is animal-strong and human-thin, and where NSAIDs remain guideline first-line care for some injuries; "ice destroys healing" is an overclaim that entry exists to size honestly. Restating their numbers here without independent verification would violate citation fidelity, so the hub inherits their tiers by reference. The one pattern worth naming once: antipyretic marketing treats the number on the thermometer as the disease, and "fever is your friend" content overextends into genuinely dangerous territory — infants, the immunocompromised, very high fevers. Both edges are argued properly in the siblings.

Mechanism

The shared machinery beneath every section above is a regulation problem, not a hardware fault. Defences are expressed by ancient, conserved circuits — the cough reflex arc, the hypothalamic fever set-point, the area postrema's chemoreceptor trigger zone for nausea, nociceptive signalling for pain, cytokine-driven motivational shutdown for sickness behaviour — and each circuit has a firing threshold that natural selection tuned, not for your comfort, and not even for your individual survival on any given day, but for the average payoff across evolutionary time.

That tuning follows signal-detection logic. Where the cost of expressing the defence is low (a bout of nausea, a day of lethargy) and the cost of failing to express it when needed is catastrophic (a swallowed toxin, an untreated infection), the optimal threshold sits far below certainty. The mathematical consequence is a system that fires early, fires often, and is frequently wrong in the safe direction. This is why the same principle honestly supports two apparently opposite conclusions: the defences deserve respect as a class, and any individual firing is quite likely an overshoot whose suppression costs nothing.

Sickness behaviour illustrates the central orchestration. Pro-inflammatory cytokines released at infection onset — interleukin-1 among them — act on the brain to produce a coordinated motivational state: lethargy, appetite loss, social withdrawal, reduced grooming. This is not the infection weakening you; it is the brain choosing to spend less on movement, digestion and sociality so more can go to the metabolically expensive febrile response. That is also why the mechanism points at rest, rather than at refusing tablets, as the defence worth honouring.

The failure mode that creates the emergency category is the same machinery without its brakes. Anaphylaxis is the defence circuitry — mast cells, histamine, vascular permeability — firing at a magnitude that becomes the lethal event itself. Hyperemesis is the nausea circuit locked open until dehydration and weight loss. In these states the regulation has failed, the smoke detector is burning the house down, and the only correct move is pharmacological override and urgent care.

Risks And Contraindications

The risks of this topic are mostly risks of misapplying the framework, and they run in both directions.

Risks of never-suppress thinking — the graver direction. Refusing epinephrine in anaphylaxis kills; the documented real-world failure is delay. Framing pregnancy nausea as protective delays care for hyperemesis. Extending the narrow dysentery caution to all diarrhoea leaves people under-treated and — worse — distracts from rehydration, the part with the mortality evidence. Reading the adaptive-mood literature as a reason to stop antidepressants is a distortion its own authors reject. Never stop or avoid a medicine a clinician has prescribed on the strength of anything in this entry.

Risks of suppress-everything thinking. Overriding sickness behaviour to keep working spends the energy the immune response was budgeted; antimotility monotherapy in bloody, febrile diarrhoea risks prolonging invasive infection; masking acute pain in order to keep loading damaged tissue risks converting a signal into a bigger injury; and blanket antipyretic and NSAID use carries the possible trades the sibling entries weigh — trades whose evidence is animal-strong and human-thin for injury inflammation, and largely not confirmed by human trials for fever.

Populations where the defaults change. Infants and young children (loperamide generally avoided; fever thresholds different — see the fever entry; and aspirin is never used for fever in children or teenagers — Reye's syndrome risk); pregnancy (treatment decisions belong with the treating clinician, and first-line antiemetics are endorsed); the immunocompromised and the elderly (blunted defences mean absence of fever or pain does not rule out serious illness).

Red flags — urgent care, no framework applies: signs of anaphylaxis after an exposure; any fever in a baby under three months old; blood in stool with fever; severe dehydration or inability to keep fluids down (pregnant or not); any fever with stiff neck, confusion, or a rash that does not fade under pressure; breathing difficulty; chest pain; worst-ever headache; an injury with inability to bear weight, visible deformity, or numbness; thoughts of self-harm.

Controversy

Nature of the controversy. This is a framing war more than a data war. The underlying findings are mostly not in dispute; what is contested is which half of the smoke detector principle gets quoted, and by whom.

Position A — "defences are wisdom; suppression is interference." Best evidence: the adaptive architecture is real — sickness behaviour is centrally orchestrated energy conservation (Hart's synthesis and the rodent cytokine work), acute pain's protective role is demonstrated by the catastrophic natural experiment of its congenital absence, and the fever and inflammation questions in the sibling entries show suppression is not automatically free. Where it overreaches: it silently converts "this system evolved" into "this firing is useful," which the smoke detector principle itself forbids — most firings of a cheaply expressed defence are overshoots. Its overreach is at its most dangerous in the emergency category, where the defence is the lethal event, and in mood, where it becomes an argument against treating depression.

Position B — "symptoms are noise; comfort and function are the goals." Best evidence: the best-studied suppressions genuinely show no documented outcome cost — guideline-endorsed antiemetics in pregnancy, loperamide in simple traveller's diarrhoea, night-time relief that protects sleep (where the sleep-immune susceptibility data give suppression a positive rationale); and no evidence shows cough suppression prolongs a cold. Where it overreaches: it markets working through infection — overriding the one defence, rest, with the strongest adaptive logic — using products that in the flagship case (cough) cannot be shown to work at all; and it ignores the narrow but real bars (dysentery, masked pain under load) that the guidelines themselves draw.

The funding/bias dimension — cui bono, both ways. The suppress side is funded by one of the largest OTC categories in existence: cough-and-cold, antidiarrhoeal and analgesic marketing all monetise continuity — the workday, the trip, the workout — and none of it mentions the exclusions. The never-suppress side is funded too: naturalist wellness media monetises distrust of medicine, and "your body knows best" content converts an evolutionary half-truth into engagement and supplement sales. Neither camp funds the two interventions with the best evidence in this entry — rest and rehydration — because nobody owns them.

Realised Position: Defences earn a moment's respect, not obedience. Ask three questions of any symptom: is this firing plausibly doing its job right now (rest during infection usually is); is suppression documented to cost anything here (usually it is not — and where it is, the sibling entries say so); and is this one of the red-flag states where the defence itself is the emergency (then treat, urgently, without philosophy). Comfort is a legitimate treatment goal. Prescribed medicines are never overridden by this framework. And the two unglamorous moves neither industry sells — sleeping and rehydrating — carry more evidence than almost everything sold alongside them.

Cross-Pillar Connections

• fever_and_sickness_behaviour_evidence — owns the fever half of this hub's central trade: fever's antimicrobial function versus antipyretic comfort, including the null human trial evidence on comfort dosing and the danger thresholds this hub only gestures at.
• acute_injury_inflammation_ice_and_nsaids — owns the injury half: whether blunting adaptive inflammation with ice and NSAIDs costs healing — the most-studied suppression trade in the batch, with the honest caveat that its human evidence is thinner than its animal evidence.
• muscle_soreness_recovery_doms — soreness as a benign, information-poor defence signal; the low-stakes end of the pain spectrum this hub's acute-signal line opens.
• common_cold_prevention_and_treatment — the per-remedy detail behind this hub's cough and cold routing, including what actually has evidence (little) and what to do instead.
• illness_inflammation_and_sleep_disruption — the mechanics behind this hub's clearest pro-suppression case: how illness fragments sleep and why protecting sleep during infection is a recovery act.
• immune_function_cross_pillar_optimisation — the standing immune-support base rate on which every acute decision in this hub sits.
• hormesis_and_adaptive_stress — the same adaptive-response logic applied to deliberate stressors; the conceptual sibling of "the defence is doing work."
• stress_response_is_adaptive_but_context_dependent — the psychological twin of this hub's thesis: the stress response, like the defences here, is adaptive machinery whose individual firings are often overshoots.
• anhedonia_reward_recovery — where this hub's low-mood routing lands: reward-system recovery and the clinical territory this hub deliberately does not carry.
• hay_fever_allergic_rhinitis_sleep_protocol — a defence misfiring against a harmless target, where suppression is the correct default; the benign end of the machinery whose catastrophic end is anaphylaxis.

What would change our mind

Falsifiability: explicit upgrade/downgrade criteria from source

• On the framework: the smoke detector principle is theory; a body of trials showing that suppressing specific defences in ordinary illness consistently worsens outcomes would push the whole hub toward "respect by default" — no such body currently exists.
• On cough: well-conducted modern RCTs showing a specific OTC antitussive meaningfully shortens or eases acute cough would retire the "barely works" irony; conversely, trials showing cough suppression prolongs respiratory infection would create a cost where none is currently documented.
• On rest: a randomised or well-instrumented prospective test of activity versus rest during acute infection with hard outcomes would convert the sickness-behaviour section from mechanism-plus-inference to outcome evidence, in either direction.
• On pregnancy nausea: a design that separates hCG-driven viability from the nausea itself (mediation analyses across large cohorts, or genetic instruments for nausea propensity) showing independent protective effect would promote the embryo-protection hypothesis; failure to separate them keeps it Emerging indefinitely.
• On diarrhoea: modern trial evidence that antimotility agents are harmful even in afebrile, non-bloody illness would widen the bar; evidence that they are safe in dysentery alongside antibiotics is already partially emerging and would narrow it.
• On low mood: any interventional evidence that watchful waiting beats treatment for clinically significant depression would be revolutionary — none exists, and its absence is why the treatment rail stands.
• What would NOT move us: more evolutionary storytelling in either direction — adaptationist just-so accounts can dress any symptom as functional and any suppression as safe; mechanism papers alone (a cytokine pathway is not an outcome); industry-funded symptom-score trials without objective endpoints; and viral anecdotes of either flavour, the toughed-it-out triumph and the medicated-and-fine triumph alike.

Industry bias note

Structural incentives the evidence base may reflect

The suppress-everything end. The cough-and-cold OTC category is worth billions annually and its flagship products cannot be shown to work by the best available systematic review — a review whose included trials were themselves often industry-funded, with heterogeneous, conflicting results, which is exactly the trial portfolio a category produces when it needs shelf claims rather than answers. Antidiarrhoeal marketing sells the trip and the workday and omits the bloody-stool exclusion from every advert. Night-time multi-symptom products bundle a directionally sound idea (protect sleep) with sedating antihistamines and price premiums the idea does not require. Branded doxylamine-pyridoxine was marketed hard off modest, contested effect sizes. The common thread: continuity is the product — the promise that no defence need ever cost you a day.

The never-suppress end. Wellness naturalism monetises the mirror image: distrust. "Your body knows best" converts Hart and Nesse's careful science into content that shames antiemetic use in pregnancy, reframes depression treatment as silencing a message, and celebrates toughing out states that have red-flag lists for a reason. Its revenue is engagement, courses and supplements positioned as the natural alternative — and its overreach concentrates precisely where the stakes are highest, because the emergency category is where "trust the body" is most dramatic and most wrong.

The clean signal. Follow what neither side can monetise. Rest has no SKU. Oral rehydration solution costs pennies and carries a mortality-reduction record almost nothing on the pharmacy shelf can match. Sleep during illness is free. The Cochrane cough review was independent; the WHO/UNICEF rehydration position and the WAO anaphylaxis guidance are as close to conflict-free consensus as this territory gets. When the unownable interventions and the unconflicted reviews all point the same way — respect rest, rehydrate, treat comfort honestly, escalate the red flags — that convergence is the signal.

Defensive Symptoms and When to Blunt Them